Product Details
| Product Name:
Brilaroxazine |
CAS No.:
1239729-06-6 |
| Purity:
99.36% |
Supply Ability:
10g |
| Release date:
2025/10/23 |
Product Introduction
Bioactivity
| Name | Brilaroxazine |
| Description | Brilaroxazine (RP5063) is a potent multimodal dopamine/5-HT modulator. Brilaroxazine is a partial agonist of dopamine D2, D3, and D4 receptors, 5-HT1A (Ki =1.5 nM) and 5-HT2A (Ki = 2.5 nM), and has antagonist activity 5-HT2B, and 5-HT7 receptors with Kis of 0.19 nM and 2.7 nM, respectively. Brilaroxazine can be used for research about cognitive impairments in neuropsychiatric and neurological diseases. |
| In vivo | Brilaroxazine (10 mg/kg) had efficacy in PAH, and mitigated the functional and structural effects of MCT-induced PAH, with significant improvements in pulmonary hemodynamics, right ventricular (RV) hypertrophy, SO2, and pulmonary blood vessel structural changes[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 95 mg/mL (210.94 mM), Sonication is recommended.
|
| Keywords | syndrome,ADHD | Serotonin Receptor | RP-5063 | RP 5063 | Pulmonary | Parkinson | PAH | Inhibitor | inhibit | hypertension | DopamineReceptor | Dopamine Receptor | disorder,Tourette | depressive | D4 receptor | D4 Receptor | D3 Receptor | D3 receptor | D2 receptor | D2 Receptor | cardiac | Brilaroxazine | autism | arterial | Alzheimer | 5-hydroxytryptamine Receptor | 5HTReceptor | 5-HT7 Receptor | 5-HT7 | 5-HT2B Receptor | 5-HT2B | 5-HT2A Receptor | 5-HT2A | 5-HT1A Receptor | 5-HT1A | 5-HT Receptor | 5HT Receptor |
| Inhibitors Related | Alverine citrate | Dapoxetine hydrochloride | Clozapine N-Oxide | Octopamine hydrochloride | D-Menthol | Citicoline | Amitriptyline hydrochloride | Oxolinic acid | Trazodone hydrochloride | Mianserin hydrochloride | Fluoxetine hydrochloride | Cinchonidine |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
CAS:15790-91-7
$38.00 / 1mg
-
CAS:313268-18-7
$30.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$107.00/1mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-10-23 |
United States